Effect of Parecoxib sodium combined with esketamine and incision infiltration on postoperative analgesia and postoperative delirium

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400090230

Enrollment

Unknown

Registered

2024-09-26

Start date

2021-12-07

Completion date

Unknown

Last updated

2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Interventions

Control Group :Sufentanil postoperative analgesia

experimental group:parecoxib sodium sequential administration, ropivacaine incision infiltration, and esketamine postoperative analgesia

Eligibility

Sex/Gender

All

Age

43 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 18-65 years old, body mass index 18.5-27.9, ASA grade I to III, signed informed consent and voluntarily received postoperative controlled intravenous analgesia (PCIA)

Exclusion criteria

Exclusion criteria: (1) minimental state examination (MMSE) score <24; (2) Patients with low education level or communication barriers, who can not complete the preoperative cognitive function test; (3) Patients with a history of severe gastrointestinal ulcers, psychosis or nervous system. (4) intolerant or allergic to drugs related to the experiment. (5) People who have taken sedation or antipsychotic drugs for a long time. (6) Combined with other major diseases, such as immune system, blood system diseases. (7) Patients with poor hypertension control and a history of vertigo.

Design outcomes

Primary

Measure	Time frame
Postoperative pain score;	—

Secondary

Measure	Time frame
The incidence of postoperative delirium;Postoperative interleukin-6 concentration;	—

Countries

China

Contacts

Public ContactJing Liu

Taian City Central Hospita

jingjilidebaihe@126.com+86 186 6089 7892

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026